{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# SPLASH and OASIS: Reference-Free Genomic Analysis\n",
    "\n",
    "## A Statistical Framework for Biological Discovery\n",
    "\n",
    "------------------------------------------------------------------------\n",
    "\n",
    "## Overview\n",
    "\n",
    "**SPLASH** (Statistically Primary aLignment Agnostic Sequence Homing) +\n",
    "**OASIS** (Optimized Adaptive Statistic for Inferring Structure) = A\n",
    "unified approach for reference-free genomic analysis\n",
    "\n",
    "### Key Innovation\n",
    "\n",
    "-   Direct analysis of raw sequencing data without reference genomes\n",
    "-   Statistically rigorous framework with finite-sample validity\n",
    "-   Interpretable results with biological meaning\n",
    "\n",
    "------------------------------------------------------------------------\n",
    "\n",
    "## The Problem with Current Approaches\n",
    "\n",
    "### Traditional Genomics Workflow\n",
    "\n",
    "1.  **Reference Alignment** → Computational bottleneck\n",
    "2.  **Chi-squared (χ²) Test** → Statistical limitations\n",
    "3.  **Post-hoc Analysis** → No built-in interpretability\n",
    "\n",
    "### Limitations of χ² Test\n",
    "\n",
    "-   **No finite-sample validity** - relies on asymptotic approximations\n",
    "-   **High sensitivity to noise** - rejects null for biologically\n",
    "    uninteresting reasons\n",
    "-   **No interpretability** - doesn’t explain WHY the null was rejected\n",
    "-   **Computational intensity** - requires full alignment pipeline\n",
    "\n",
    "------------------------------------------------------------------------\n",
    "\n",
    "## SPLASH: The Data Processing Engine\n",
    "\n",
    "### Core Concept: Anchor-Target Pairs\n",
    "\n",
    "-   **Anchor**: Fixed k-mer sequence (k=27 by default)\n",
    "-   **Target**: Variable k-mer at fixed offset downstream\n",
    "-   Creates contingency tables automatically from raw reads\n",
    "\n",
    "### Biological Applications Detected\n",
    "\n",
    "1.  **Viral strain mutations** (SARS-CoV-2, M. tuberculosis)\n",
    "2.  **Alternative splicing** (single-cell level)\n",
    "3.  **Immune receptor diversity** (B/T cell receptors)\n",
    "4.  **Tissue-specific isoforms** (cross-species)\n",
    "5.  **Environmental variation** (seasonal, geographic)\n",
    "\n",
    "------------------------------------------------------------------------\n",
    "\n",
    "## OASIS: The Statistical Framework\n",
    "\n",
    "### Why OASIS over χ²?\n",
    "\n",
    "#### P-value Characteristics\n",
    "\n",
    "**Most Appealing**: **Finite-sample validity** + **Speed** - Closed-form\n",
    "P-value bounds (no simulation needed) - Valid for ANY number of\n",
    "observations - Computationally efficient (no alignment required)\n",
    "\n",
    "**Essential Characteristic**: **Robustness to unwanted variability** -\n",
    "Focuses on structured deviations - Averages out unstructured noise -\n",
    "Biologically meaningful results\n",
    "\n",
    "### Mathematical Foundation\n",
    "\n",
    "    OASIS Test Statistic: S = f^T X̃ c\n",
    "\n",
    "Where: - X̃ = centered and normalized contingency table - f = row\n",
    "embedding (binary: 0/1) - c = column embedding (continuous)\n",
    "\n",
    "------------------------------------------------------------------------\n",
    "\n",
    "## Handling Unwanted Variability\n",
    "\n",
    "### The Problem in High-Throughput Data\n",
    "\n",
    "-   **Technical noise** from sequencing errors\n",
    "-   **Batch effects** from experimental conditions  \n",
    "-   **Overdispersion** from biological sampling\n",
    "-   **Contamination** from mixed samples\n",
    "\n",
    "### OASIS Solution: Structured vs Unstructured Deviations\n",
    "\n",
    "#### Structured (Biologically Meaningful)\n",
    "\n",
    "-   Strain differences\n",
    "-   Cell-type specific expression\n",
    "-   Developmental stages\n",
    "-   Treatment responses\n",
    "\n",
    "#### Unstructured (Technical Noise)\n",
    "\n",
    "-   Random sequencing errors\n",
    "-   Low-count artifacts\n",
    "-   Equipment variation\n",
    "-   Sample contamination\n",
    "\n",
    "**Key Insight**: OASIS computes bilinear forms that average out\n",
    "unstructured noise while amplifying structured biological signals.\n",
    "\n",
    "------------------------------------------------------------------------\n",
    "\n",
    "## Biological Interpretability\n",
    "\n",
    "### Built-in Decomposition\n",
    "\n",
    "Unlike χ² which only provides a rejection decision, OASIS provides:\n",
    "\n",
    "1.  **Sample Groupings** (via column embeddings c)\n",
    "    -   Which samples cluster together?\n",
    "    -   What biological conditions are similar?\n",
    "2.  **Feature Importance** (via row embeddings f)\n",
    "    -   Which genomic regions drive the differences?\n",
    "    -   What biological processes are involved?\n",
    "3.  **Effect Size Measures**\n",
    "    -   Magnitude of biological differences\n",
    "    -   Confidence in biological relevance\n",
    "\n",
    "### Real Biological Examples\n",
    "\n",
    "#### SARS-CoV-2 Strain Detection\n",
    "\n",
    "-   **100% accuracy** distinguishing Omicron vs Delta\n",
    "-   **No reference genome** required\n",
    "-   **No metadata** needed\n",
    "-   Automatically identifies strain-defining mutations\n",
    "\n",
    "#### Single-Cell Applications\n",
    "\n",
    "-   **Cell-type specific** alternative splicing\n",
    "-   **HLA allele-specific** expression patterns\n",
    "-   **Immune receptor diversity** detection\n",
    "\n",
    "------------------------------------------------------------------------\n",
    "\n",
    "## Critical Assessment: Why χ² is an Inadequate Comparator\n",
    "\n",
    "### The Problem with χ² as Benchmark\n",
    "\n",
    "**χ² represents 1990s methodology** - not current best practices in\n",
    "genomics:\n",
    "\n",
    "❌ **No count transformation** (log, variance stabilization)  \n",
    "❌ **No normalization** (library size, composition bias)  \n",
    "❌ **No batch effect correction** (technical confounders)  \n",
    "❌ **Raw count assumptions** (Poisson vs. negative binomial)\n",
    "\n",
    "### What Should Have Been Compared: Modern RNA-seq Methods\n",
    "\n",
    "#### Appropriate Comparators (Risso et al. 2014 framework):\n",
    "\n",
    "1.  **DESeq2** - Negative binomial GLMs with size factor normalization\n",
    "2.  **edgeR** - Empirical Bayes moderated t-tests  \n",
    "3.  **limma-voom** - Variance modeling + linear models\n",
    "4.  **RUVSeq** - Remove Unwanted Variation methods\n",
    "5.  **sva/ComBat** - Surrogate variable analysis\n",
    "\n",
    "#### Standard RNA-seq Pipeline:\n",
    "\n",
    "    Raw Counts → Filtering → Normalization → Transformation → \n",
    "    Batch Correction → Differential Analysis → Multiple Testing\n",
    "\n",
    "### Missing Benchmarking Components\n",
    "\n",
    "#### What’s Missing from OASIS Evaluation:\n",
    "\n",
    "1.  **Comprehensive benchmark datasets** (not cherry-picked examples)\n",
    "2.  **Objective performance metrics** beyond p-values\n",
    "3.  **Comparison with state-of-the-art** RNA-seq methods\n",
    "4.  **Real data validation** across multiple studies\n",
    "5.  **Computational scalability** assessment\n",
    "\n",
    "### Performance Comparison: Current Limitations\n",
    "\n",
    "| Aspect             | Current Paper      | What’s Needed                 |\n",
    "|--------------------|--------------------|-------------------------------|\n",
    "| **Comparator**     | χ² test (outdated) | DESeq2, edgeR, limma-voom     |\n",
    "| **Data Selection** | Curated examples   | Comprehensive benchmarks      |\n",
    "| **Metrics**        | P-values only      | Sensitivity, specificity, FDR |\n",
    "| **Validation**     | Selected datasets  | Multiple independent studies  |\n",
    "| **Scalability**    | Not assessed       | Runtime, memory, large-scale  |\n",
    "\n",
    "------------------------------------------------------------------------\n",
    "\n",
    "## Practical Advantages\n",
    "\n",
    "### Speed and Scalability\n",
    "\n",
    "-   **500× reduction** in computational load vs traditional alignment\n",
    "-   **Closed-form statistics** - no permutation testing needed\n",
    "-   **Parallelizable** across genomic regions\n",
    "\n",
    "### No Reference Dependence\n",
    "\n",
    "-   Works with **incomplete genomes**\n",
    "-   Effective for **non-model organisms**\n",
    "-   Discovers **novel biology** not in references\n",
    "\n",
    "### Statistical Validity\n",
    "\n",
    "-   **Finite-sample P-values** for any dataset size\n",
    "-   **Multiple testing correction** built-in\n",
    "-   **Interpretable effect sizes**\n",
    "\n",
    "------------------------------------------------------------------------\n",
    "\n",
    "## Key Biological Discoveries Enabled\n",
    "\n",
    "### 1. Pathogen Surveillance\n",
    "\n",
    "-   **Reference-free** strain classification\n",
    "-   **Real-time** outbreak detection\n",
    "-   **Evolutionary** relationship inference\n",
    "\n",
    "### 2. Single-Cell Genomics\n",
    "\n",
    "-   **Cell-type specific** isoform detection\n",
    "-   **Allele-specific** expression patterns\n",
    "-   **Developmental** trajectory analysis\n",
    "\n",
    "### 3. Non-Model Organisms\n",
    "\n",
    "-   **Environmental genomics** (eelgrass + diatom associations)\n",
    "-   **Comparative genomics** (octopus tissue-specific transcripts)\n",
    "-   **Conservation biology** applications\n",
    "\n",
    "### 4. Immune System Analysis\n",
    "\n",
    "-   **B/T cell receptor** diversity quantification\n",
    "-   **Cross-species** immune evolution\n",
    "-   **Functional** repertoire analysis\n",
    "\n",
    "------------------------------------------------------------------------\n",
    "\n",
    "## Statistical Framework Details\n",
    "\n",
    "### Finite-Sample P-value Bound\n",
    "\n",
    "    P(|S| ≥ s) ≤ 2 exp(-2s²/(1-γ))\n",
    "\n",
    "-   **γ** measures similarity between column embedding and sample counts\n",
    "-   **Valid for any number of observations**\n",
    "-   **No distributional assumptions**\n",
    "\n",
    "### Asymptotic Distribution\n",
    "\n",
    "Under null hypothesis:\n",
    "\n",
    "    S ~ N(0, σ²f ||c||²)\n",
    "\n",
    "-   Matches finite-sample bounds asymptotically\n",
    "-   Enables power calculations\n",
    "-   Provides theoretical foundation\n",
    "\n",
    "------------------------------------------------------------------------\n",
    "\n",
    "## Implementation and Data Analysis\n",
    "\n",
    "### Available Data Resources\n",
    "\n",
    "-   **SARS-CoV-2 datasets**: France (103 samples), South Africa\n",
    "    (multiple strains)\n",
    "-   **M. tuberculosis**: 25 isolates, sub-lineage classification\n",
    "-   **Single-cell RNA-seq**: Human lung atlas, immune cells\n",
    "-   **Cross-species**: Mouse lemur, octopus, eelgrass\n",
    "\n",
    "### R Analysis Framework\n",
    "\n",
    "``` r\n",
    "# Pseudocode for OASIS implementation\n",
    "oasis_analysis <- function(contingency_table) {\n",
    "  # 1. Center and normalize\n",
    "  X_tilde <- center_normalize(contingency_table)\n",
    "  \n",
    "  # 2. Optimize embeddings\n",
    "  embeddings <- optimize_embeddings(X_tilde)\n",
    "  \n",
    "  # 3. Compute test statistic\n",
    "  S <- compute_statistic(X_tilde, embeddings)\n",
    "  \n",
    "  # 4. Calculate P-value bound\n",
    "  p_value <- finite_sample_bound(S, embeddings)\n",
    "  \n",
    "  # 5. Interpret results\n",
    "  interpretation <- biological_interpretation(embeddings)\n",
    "  \n",
    "  return(list(p_value = p_value, \n",
    "              interpretation = interpretation,\n",
    "              effect_size = effect_size))\n",
    "}\n",
    "```\n",
    "\n",
    "------------------------------------------------------------------------\n",
    "\n",
    "## Future Directions and Extensions\n",
    "\n",
    "### Methodological Advances\n",
    "\n",
    "1.  **Tensor Extensions** - Multi-dimensional contingency tables\n",
    "2.  **Adaptive Methods** - Data-driven parameter selection\n",
    "3.  **Meta-Analysis** - Combining multiple studies\n",
    "4.  **Causal Inference** - Beyond association to causation\n",
    "\n",
    "### Biological Applications\n",
    "\n",
    "1.  **Precision Medicine** - Patient stratification\n",
    "2.  **Drug Discovery** - Target identification\n",
    "3.  **Agricultural Genomics** - Crop improvement\n",
    "4.  **Conservation Biology** - Species monitoring\n",
    "\n",
    "------------------------------------------------------------------------\n",
    "\n",
    "## Conclusions\n",
    "\n",
    "### Why OASIS Matters for Biology\n",
    "\n",
    "1.  **Democratizes genomic analysis** - No need for high-quality\n",
    "    references\n",
    "2.  **Accelerates discovery** - Direct analysis of raw data\n",
    "3.  **Provides biological insight** - Built-in interpretability\n",
    "4.  **Statistically rigorous** - Finite-sample validity\n",
    "\n",
    "### Why OASIS Matters for Statistics\n",
    "\n",
    "1.  **Novel approach** to contingency table analysis\n",
    "2.  **Robust to realistic noise** models\n",
    "3.  **Computationally efficient** closed-form solutions\n",
    "4.  **Interpretable decomposition** of complex data\n",
    "\n",
    "### The Bottom Line\n",
    "\n",
    "**OASIS + SPLASH = A paradigm shift from “alignment-first” to\n",
    "“statistics-first” genomic analysis**\n",
    "\n",
    "## Next Steps: Rigorous Benchmarking Framework\n",
    "\n",
    "### Proposed Comprehensive Evaluation\n",
    "\n",
    "#### 1. **Benchmark Datasets** (Unbiased Selection)\n",
    "\n",
    "-   **GEUVADIS** - 1000 Genomes RNA-seq data\n",
    "-   **GTEx** - Multi-tissue expression atlas  \n",
    "-   **TCGA** - Cancer vs normal comparisons\n",
    "-   **Single-cell atlases** - Cell type classification\n",
    "-   **Time-course studies** - Developmental trajectories\n",
    "\n",
    "#### 2. **State-of-the-Art Comparators**\n",
    "\n",
    "``` r\n",
    "# Modern RNA-seq analysis pipeline comparators\n",
    "comparators <- c(\n",
    "  \"DESeq2\",           # Standard for bulk RNA-seq\n",
    "  \"edgeR\",            # Alternative GLM approach  \n",
    "  \"limma-voom\",       # Variance modeling\n",
    "  \"RUVSeq\",           # Unwanted variation removal\n",
    "  \"sva\",              # Surrogate variable analysis\n",
    "  \"scran/scater\",     # Single-cell methods\n",
    "  \"Seurat\",           # Single-cell clustering\n",
    "  \"MAST\"              # Single-cell differential expression\n",
    ")\n",
    "```\n",
    "\n",
    "#### 3. **Objective Performance Metrics**\n",
    "\n",
    "-   **Sensitivity/Specificity** on ground truth datasets\n",
    "-   **False Discovery Rate** control under null\n",
    "-   **Area Under ROC Curve** for classification\n",
    "-   **Concordance** with known biology\n",
    "-   **Computational efficiency** (time/memory)\n",
    "-   **Reproducibility** across technical replicates\n",
    "\n",
    "#### 4. **Validation Strategy**\n",
    "\n",
    "``` r\n",
    "validation_framework <- list(\n",
    "  # Spike-in controls with known truth\n",
    "  spike_in_validation = \"ERCC, SIRV controls\",\n",
    "  \n",
    "  # Cross-platform concordance  \n",
    "  platform_validation = \"Illumina vs PacBio vs Oxford Nanopore\",\n",
    "  \n",
    "  # Cross-laboratory reproducibility\n",
    "  batch_validation = \"SEQC, MAQC consortiums\",\n",
    "  \n",
    "  # Biological validation\n",
    "  functional_validation = \"qPCR, protein levels, phenotypes\"\n",
    ")\n",
    "```\n",
    "\n",
    "### Recommended Analysis Plan\n",
    "\n",
    "#### Phase 1: **Proper Normalization Integration**\n",
    "\n",
    "-   Implement **library size normalization** in SPLASH pipeline\n",
    "-   Add **variance stabilizing transformations**\n",
    "-   Include **batch effect correction** capabilities\n",
    "-   Compare with **RUVSeq framework**\n",
    "\n",
    "#### Phase 2: **Comprehensive Benchmarking**\n",
    "\n",
    "-   **Systematic evaluation** across multiple datasets\n",
    "-   **Head-to-head comparison** with modern methods\n",
    "-   **Performance profiling** under different conditions\n",
    "-   **Failure mode analysis** - when does OASIS fail?\n",
    "\n",
    "#### Phase 3: **Real-World Validation**\n",
    "\n",
    "-   **Independent datasets** not used in development\n",
    "-   **Blinded evaluation** by external researchers  \n",
    "-   **Multi-center studies** with different protocols\n",
    "-   **Longitudinal validation** - does performance hold over time?\n",
    "\n",
    "### Critical Questions for Future Work\n",
    "\n",
    "1.  **How does OASIS perform** when proper normalization is applied to\n",
    "    comparators?\n",
    "2.  **What is the computational cost** compared to optimized RNA-seq\n",
    "    pipelines?\n",
    "3.  **Does reference-free analysis** actually provide advantages over\n",
    "    well-normalized reference-based methods?\n",
    "4.  **Can OASIS integrate** with existing RNA-seq quality control\n",
    "    frameworks?\n",
    "5.  **What are the failure modes** - when should you NOT use OASIS?\n",
    "\n",
    "------------------------------------------------------------------------"
   ],
   "id": "c23a621d-3488-4582-8a33-10b41d3faabd"
  }
 ],
 "nbformat": 4,
 "nbformat_minor": 5,
 "metadata": {}
}
